Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer

June 26, 2019

We're not around right now. But you can send us an email and we'll get back to you, asap.

Start typing and press Enter to search